Richard Anthony Moulson

Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom.